NCT07249294Active, not recruiting
Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease
Multidisciplinary Program to Avoid NSAIDs or Metamizole (HepatoAINEs Study) in Patients With Advanced Chronic Liver Disease Undergoing Major Surgery
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
This study aims to implement measures to avoid the use of NSAIDs or metamizole in patients with advanced chronic liver disease (ACLD) scheduled for major surgery, which are contraindicated due to increased risk of renal dysfunction such as acute kidney injury (AKI), clinical decompensation such as ascites, and bleeding.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 1 Apr 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Parc de Salut Mar
- Diseases
- High blood pressure
- NCT number
- NCT07249294
What you commit to
- Study type: Interventional
- Planned participants: 84
- From 1 Apr 2023 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Adults (\>18 years) with ACLD scheduled for major surgery
- Exclusion Criteria: Absence of ACLD or portal hypertension, lack of informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital del Mar Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.